METASTATIC PROSTATE ADENOCARCINOMA
Clinical trials for METASTATIC PROSTATE ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PROSTATE ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PROSTATE ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to slow bone metastases in prostate cancer
Disease control OngoingThis study tests a combination of two drugs—olaparib and radium-223—in men with castration-resistant prostate cancer that has spread to bone. Olaparib blocks a protein that helps cancer cells repair themselves, while radium-223 delivers radiation directly to bone tumors. The tria…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New trial aims to cut side effects of radiation for recurrent prostate cancer
Disease control OngoingThis phase II trial tests two types of radiation therapy (proton beam or IMRT) given in fewer, larger doses for men whose prostate cancer has returned or spread to a few spots after initial treatment. The main goal is to see if this shorter course causes fewer serious side effect…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New Immune-Guiding drug shows promise in advanced prostate cancer trial
Disease control OngoingThis early-stage study tests a new drug, JNJ-78278343, that helps the body's immune T-cells find and attack prostate cancer cells. It involves 216 men with advanced prostate cancer that has spread. The main goals are to find the safest and most effective dose and to monitor side …
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New combo pill targets Hard-to-Treat prostate cancer in men with SPOP mutation
Disease control OngoingThis phase 2 trial tests a fixed-dose combination of niraparib and abiraterone acetate plus prednisone in 8 men with metastatic castration-resistant prostate cancer that has a SPOP gene mutation. The drugs work by blocking cancer cell repair and reducing inflammation. The main go…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Double-Drug attack on prostate cancer shows promise in early trial
Disease control OngoingThis phase III trial tests whether adding rucaparib to standard enzalutamide therapy helps men with metastatic castration-resistant prostate cancer live longer or delay cancer growth. The study involves 61 participants and compares the combination against enzalutamide alone. Rese…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New combo therapy aims to knock back recurrent prostate cancer
Disease control OngoingThis phase II trial is testing whether combining antiandrogen drugs (leuprolide, apalutamide, abiraterone) with precise radiation (SBRT) can control prostate cancer that has come back and spread to a few other spots in the body. The study enrolls 28 men whose cancer has 1-5 visib…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Experimental combo aims to rev up immune system against Hard-to-Treat prostate cancer
Disease control TerminatedThis phase 2 trial tests whether combining two drugs—vidutolimod and nivolumab—can help the immune system attack metastatic castration-resistant prostate cancer. Nivolumab blocks a protein that shuts down immune cells, while vidutolimod is designed to train those cells to target …
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 26, 2026 19:13 UTC
-
Diet before chemo may cut side effects in breast and prostate cancer
Symptom relief OngoingThis study tests whether eating a low-calorie diet before chemotherapy can reduce side effects like fatigue, nausea, and mouth sores, and also improve how well the treatment works. About 130 people with breast or prostate cancer will be randomly assigned to either follow the diet…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: NA • Sponsor: University of Southern California • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC